Print Page  E-mail Page  RSS  E-mail Alerts  Tearsheet 

Investor Home

Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company that develops, produces and commercializes molecular nuclear medicine, or MNM, products.

AAA is a European leader in the production and commercialization of molecular nuclear diagnostic radiopharmaceuticals for PET and SPECT. These radiopharmaceuticals are mainly used for diagnosis in clinical oncology, cardiology and neurology.

...
more >
Materials for 24 May 2017 Annual Meeting
  • Agenda & Resolutions FR | ENG
  • Board report on extraordinary resolutions FR | ENG
  • CV of proposed board member ENG
  • Lettre aux actionnaires FR
  • Comptes annuels FR
  • IFRS consolidated financial statements FR | ENG
  • 2016 Annual Report ENG
  • Auditors Report on IFRS Accounts ENG
  • Auditors report on AAA S.A. accounts FR
  • Auditors report on AAA S.A. related party transactions FR
Latest Newsmore >
05/25/17
Advanced Accelerator Applications Appoints Christine Mikail to Board of Directors
SAINT-GENIS-POUILLY, France, May 25, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an international specialist in Molecular Nuclear Medicine (MNM), today announced that Christine Mikail, J.D. has joined the Company’s board of directors as an independent non-executive director. “Ms. Mikail brings both a broad legal skillset and substantial business development experience in the pharmaceutical industry,” stated Stefano Buono, Chief Executi... 
05/18/17
Advanced Accelerator Applications Receives 2017 Industry Innovation Award from National Organization for Rare Disorders for NETSPOT®, a Diagnostic Drug for Neuroendocrine Tumors
SAINT-GENIS-POUILLY, France, May 18, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an international specialist in Molecular Nuclear Medicine (MNM), today announced that it will receive a 2017 Industry Innovation Award from the National Organization for Rare Disorders (NORD®) for NETSPOT® (gallium Ga 68 dotatate), a diagnostic drug for the localization of neuroendocrine tumors (NETs) using a positron emission tomography (PET) scan, at the NO... 
03/30/17
Advanced Accelerator Applications Signs Strategic Supply Agreement with University of Missouri for Lutetium 177
Strengthens Global Supply Chain for Lead Investigational Product Lutetium Lu 177 Dotatate (Lutathera®) and Future Lu-177 Products SAINT-GENIS-POUILLY, France, March 30, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an international specialist in Molecular Nuclear Medicine (MNM), today announced a 10-year exclusive supply agreement for lutetium 177 with the University of Missouri Research Reactor (MURR®). Through this agreement, MURR® will ... 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources